Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02921022 · ClinicalTrials.gov registry record · NA
Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma
A NA study of Pancreatic Cancer and Advanced Pancreatic Ductal Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 110
- Enrollment target
- 10
- Study locations
NCT02921022: Active NA study of Pancreatic Cancer and Advanced Pancreatic Ductal Adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT02921022 is a NA study of Pancreatic Cancer and Advanced Pancreatic Ductal Adenocarcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 110 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (72% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02921022, a NA study of Pancreatic Cancer and Advanced Pancreatic Ductal Adenocarcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 110 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA) has not approved the marketing or sale of PEGPH20, but have authorized its use in research studies with humans. PEGPH20 could shrink the cancer but it also can cause side effects. PEGPH20 is an enzyme that breaks down a specific tissue component called hyaluronan produced by some tumors. Pancreatic tumors often have a large amount of hyaluronan. The removal of hyaluronan from tumors may decrease tumor growth.
Primary Outcome
This includes any grade 2 or grade 3 thromboembolic event as defined by NCI CTCAE v4.0 found on incidental imaging, which would indicate a need for medical intervention.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG PEGPH20
Study Locations (10)
New York
- Memorial Sloan Kettering Commack - Commack
- Memorial Sloan Kettering Westchester - Harrison
- Memorial Sloan Kettering Cancer Center - New York
- Memorial Sloan Kettering Nassau - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge - Basking Ridge
- Memorial Sloan Kettering Monmouth - Middletown
- Memorial Sloan Kettering Bergen - Montvale
Connecticut
- Hartford Healthcare Cancer Institute @ Hartford Hospital - Hartford
Florida
- Miami Cancer Institute - Miami
Pennsylvania
- Lehigh Valley Health Network - Allentown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2016-10 |
| Est. Completion | 2026-10 |
| Phase | NA |
What the registry record for NCT02921022 still lists
NCT02921022 is an interventional study that assigns participants to a tested intervention. The registered 110 participants enrollment target is mid-sized for trials with a published cap, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Pancreatic Cancer appearing as the primary indexed condition, and to 3 interventions - of which Gemcitabine is the first listed.
NCT02921022 lists 10 locations in 5 states (New York, New Jersey, Connecticut).
Frequently Asked Questions
What is clinical trial NCT02921022 about?
NCT02921022 is a clinical study titled "Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma". The purpose of this study is to test any good and bad effects of the study drug called PEGPH20. PEGPH20 alone is considered investigational. The Food and Drug Administration (FDA) has not approved the marketing or sale of PEGPH20, but have authorized its use in research studies with humans. PEGPH20 ...
What is the current status of trial NCT02921022?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 110 participants. The study started on 2016-10. Estimated completion is 2026-10.
What conditions does trial NCT02921022 study?
This clinical trial studies the following conditions: Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT02921022?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), PEGPH20 (DRUG).
Who is sponsoring clinical trial NCT02921022?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02921022 being conducted?
This trial has 10 study locations across Connecticut, Florida, New Jersey, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02921022's enrollment target sits among peer trials
110 98th of 278 higher than 179 of 278 other Pancreatic Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatic Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer
RECRUITING · NA
-
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
RECRUITING · NA
-
EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
RECRUITING · NA
-
Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
RECRUITING · NA
-
Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
RECRUITING · NA
-
GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01530373 · 110 participants · Phase 2
Solifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
- NCT02379377 · 110 participants · Phase 1
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
- NCT02411773 · 110 participants · Phase 1
Sympatholysis in Chronic Kidney Disease
- NCT03245411 · 110 participants · NA
Assessment of Multi-Level Interventions to Improve Adherence to Oral Medications in Cancer Patients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia